{"id":18011,"date":"2023-06-09T00:51:00","date_gmt":"2023-06-08T16:51:00","guid":{"rendered":"https:\/\/flcube.com\/?p=18011"},"modified":"2025-01-06T18:16:13","modified_gmt":"2025-01-06T10:16:13","slug":"cde-indicates-priority-review-for-overland-adcts-zynlonta-and-beigenes-brukinsa","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=18011","title":{"rendered":"CDE Indicates Priority Review for Overland ADCT&#8217;s Zynlonta and BeiGene&#8217;s Brukinsa"},"content":{"rendered":"\n<p>The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY) Ltd\u2019s Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, and BeiGene Ltd\u2019s (<a href=\"https:\/\/www.google.com\/finance\/quote\/BGNE:NASDAQ\">NASDAQ: BGNE<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6160:HKG\">HKG: 6160<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688235:SHA\">SHA: 688235<\/a>) Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) are on track to receive priority review statuses. Both drugs are being considered for conditional approvals, with indications for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and recurrent or refractory follicular lymphoma (FL) in patients who have undergone at least second-line systemic therapy, including obinutuzumab.<\/p>\n\n\n\n<p><strong>Zynlonta&#8217;s Global Approvals and Potential for China<\/strong><br>Zynlonta received fast-track approval in the US in April 2021, marking it as the first of its kind worldwide for use in R\/R DLBCL that has received at least two lines of prior systemic therapy. It later earned conditional approval in the European Union (EU) in December of the same year. Overland ADCT BioPharma (CY) Ltd, a joint venture between China\u2019s Overland Pharmaceuticals and Swiss firm ADC Therapeutics SA (<a href=\"https:\/\/www.google.com\/finance\/quote\/ADCT:NYSE\">NYSE: ADCT<\/a>), is responsible for the development and commercialization of Zynlonta and other ADCs in Greater China. Taiwan-based Orient EuroPharma Co., Ltd has obtained exclusive agency rights to the drug in Taiwan and Singapore. Positive results from the Phase II regulatory OL-ADCT-402-001 study for Zynlonta in R\/R DLBCL have allowed Overland ADCT to file for marketing approval in China.<\/p>\n\n\n\n<p><strong>Brukinsa&#8217;s Expanded Indications and Regulatory Milestones<\/strong><br>Brukinsa is already approved in the US for a range of indications, including Waldenstrom&#8217;s macroglobulinemia (WM), mantle-cell lymphoma (MCL), and marginal zone lymphoma (MZL). The FDA had delayed the PDUFA for the drug to fully review additional data provided, including the eventual remission evaluation results of the ALPINE study. Brukinsa was first approved in the United States in November 2019 to treat MCL in previously treated adult patients. In China, Brukinsa was approved in June 2020 for both MCL and for previously treated adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Regulatory approvals were updated in May 2023, with two new indication approvals: newly diagnosed CLL or SLL and newly diagnosed WM.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,2695,185,2092,16,1852,847,846,3046,2696,2749,2694,80,848,33],"class_list":["post-18011","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-adc-therapeutics","tag-beigene","tag-beone-medicines","tag-cancer","tag-conditional-approvals","tag-hkg-6160","tag-nasdaq-bgne","tag-nasdaq-onc","tag-nyse-adct","tag-overland-adct-biopharma","tag-overland-pharmaceuticals","tag-priority-reviews","tag-sha-688235","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CDE Indicates Priority Review for Overland ADCT&#039;s Zynlonta and BeiGene&#039;s Brukinsa - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY) Ltd\u2019s Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, and BeiGene Ltd\u2019s (NASDAQ: BGNE, HKG: 6160, SHA: 688235) Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) are on track to receive priority review statuses. Both drugs are being considered for conditional approvals, with indications for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and recurrent or refractory follicular lymphoma (FL) in patients who have undergone at least second-line systemic therapy, including obinutuzumab.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=18011\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CDE Indicates Priority Review for Overland ADCT&#039;s Zynlonta and BeiGene&#039;s Brukinsa\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=18011\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-08T16:51:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-06T10:16:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CDE Indicates Priority Review for Overland ADCT&#8217;s Zynlonta and BeiGene&#8217;s Brukinsa\",\"datePublished\":\"2023-06-08T16:51:00+00:00\",\"dateModified\":\"2025-01-06T10:16:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011\"},\"wordCount\":368,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"ADC Therapeutics\",\"BeiGene\",\"BeOne Medicines\",\"Cancer\",\"Conditional approvals\",\"HKG: 6160\",\"NASDAQ: BGNE\",\"NASDAQ: ONC\",\"NYSE: ADCT\",\"Overland ADCT BioPharma\",\"Overland Pharmaceuticals\",\"Priority reviews\",\"SHA: 688235\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18011#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=18011\",\"name\":\"CDE Indicates Priority Review for Overland ADCT's Zynlonta and BeiGene's Brukinsa - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-06-08T16:51:00+00:00\",\"dateModified\":\"2025-01-06T10:16:13+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY) Ltd\u2019s Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, and BeiGene Ltd\u2019s (NASDAQ: BGNE, HKG: 6160, SHA: 688235) Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) are on track to receive priority review statuses. Both drugs are being considered for conditional approvals, with indications for the treatment of recurrent\\\/refractory diffuse large B-cell lymphoma (R\\\/R DLBCL) and recurrent or refractory follicular lymphoma (FL) in patients who have undergone at least second-line systemic therapy, including obinutuzumab.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=18011\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=18011#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CDE Indicates Priority Review for Overland ADCT&#8217;s Zynlonta and BeiGene&#8217;s Brukinsa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CDE Indicates Priority Review for Overland ADCT's Zynlonta and BeiGene's Brukinsa - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY) Ltd\u2019s Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, and BeiGene Ltd\u2019s (NASDAQ: BGNE, HKG: 6160, SHA: 688235) Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) are on track to receive priority review statuses. Both drugs are being considered for conditional approvals, with indications for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and recurrent or refractory follicular lymphoma (FL) in patients who have undergone at least second-line systemic therapy, including obinutuzumab.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=18011","og_locale":"en_US","og_type":"article","og_title":"CDE Indicates Priority Review for Overland ADCT's Zynlonta and BeiGene's Brukinsa","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=18011","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-06-08T16:51:00+00:00","article_modified_time":"2025-01-06T10:16:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=18011#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=18011"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CDE Indicates Priority Review for Overland ADCT&#8217;s Zynlonta and BeiGene&#8217;s Brukinsa","datePublished":"2023-06-08T16:51:00+00:00","dateModified":"2025-01-06T10:16:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=18011"},"wordCount":368,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","ADC Therapeutics","BeiGene","BeOne Medicines","Cancer","Conditional approvals","HKG: 6160","NASDAQ: BGNE","NASDAQ: ONC","NYSE: ADCT","Overland ADCT BioPharma","Overland Pharmaceuticals","Priority reviews","SHA: 688235","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=18011#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=18011","url":"https:\/\/flcube.com\/?p=18011","name":"CDE Indicates Priority Review for Overland ADCT's Zynlonta and BeiGene's Brukinsa - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-06-08T16:51:00+00:00","dateModified":"2025-01-06T10:16:13+00:00","description":"The Center for Drug Evaluation (CDE) in China has indicated that Overland ADCT BioPharma (CY) Ltd\u2019s Zynlonta (loncastuximab tesirine), an antibody-drug conjugate (ADC) targeting CD19, and BeiGene Ltd\u2019s (NASDAQ: BGNE, HKG: 6160, SHA: 688235) Bruton\u2019s tyrosine kinase (BTK) inhibitor Brukinsa (zanubrutinib) are on track to receive priority review statuses. Both drugs are being considered for conditional approvals, with indications for the treatment of recurrent\/refractory diffuse large B-cell lymphoma (R\/R DLBCL) and recurrent or refractory follicular lymphoma (FL) in patients who have undergone at least second-line systemic therapy, including obinutuzumab.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=18011#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=18011"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=18011#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CDE Indicates Priority Review for Overland ADCT&#8217;s Zynlonta and BeiGene&#8217;s Brukinsa"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18011","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=18011"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18011\/revisions"}],"predecessor-version":[{"id":18013,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/18011\/revisions\/18013"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=18011"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=18011"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=18011"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}